CND261

CND261 is a bispecific antibody engineered to simultaneously target CD20 on B-cells and CD3 on T-cells. This design enables T-cell mediated cytotoxicity against CD20-expressing B-cells, facilitating the depletion of pathogenic B-cell populations implicated in autoimmune diseases. The molecule features low affinity for CD3 to minimize excessive T-cell activation, aiming for potent yet selective B-cell depletion with an improved safety profile compared to existing therapies. Initially evaluated in oncology (B-cell malignancies), CND261 is now being developed as a novel therapy for autoimmune disorders such as rheumatoid arthritis, systemic sclerosis, IgA nephropathy, myasthenia gravis, and systemic lupus erythematosus. Its mechanism leverages targeted immune modulation through T-cell engagement and broad B-cell subtype targeting[1][2][3][4][7].

Other names

CD20xCD3 bispecific antibodyCD-20xCD3 bispecific antibodyCD 20xCD3 bispecific antibody